Latest News and Press Releases

TeleDaaS™ Launches Y90 Treatment Planning Service and Announces Pilot Program for Early Adopters

TeleDaaS revolutionizes radiopharmaceutical research by delivering highly-scalable, clinical-grade dosimetry to accelerate cancer treatment breakthroughs.

Dublin, Aug. 29, 2022 (GLOBE NEWSWIRE) -- The "Global Thermoluminescent Dosimeter (TLD) Services Market (2022-2027) by Type, Industry, Dosimetry Service, Geography, Competitive Analysis, and the...

IBA vend RadioMed, partie d’IBA Dosimétrie, à IZI Medical Products Le reste de la division Dosimétrie restera au sein du groupe IBA. L’évaluation stratégique de cette division est maintenant...

IBA sells RadioMed, part of IBA Dosimetry, to IZI Medical Products Remainder of Dosimetry division retained, strategic review concluded Louvain-la-Neuve, Belgium, 17 December 2019 - IBA (Ion Beam...

Louvain-la-Neuve, Belgique, le 14 novembre 2019 - IBA (Ion Beam Applications S.A., EURONEXT), le premier fournisseur mondial de solutions de protonthérapie pour le traitement du cancer, publie...

Louvain-la-Neuve, Belgium, 14 November, 2019 - IBA (Ion Beam Applications SA), the world’s leading provider of proton therapy solutions for the treatment of cancer, today announces its business update...

Hausse des revenus du groupe à hauteur de 13,8% pour atteindre EUR 102,8 millions, avec des revenus supérieurs attendus au second semestre 2019Position de leader confirmée sur le marché, tous secteurs...

Group revenue up 13.8% to EUR 102.8 million, with higher revenues expected over H2 2019Market leadership confirmed in all business lines and major geographiesTwo Proteus®ONE solutions sold in Italy...